Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHORUS: Comprehensive HHT (Hereditary Hemorrhagic Telangiectasia) Outcomes Registry of the United States

NCT06259292 is registered in ClinicalTrials.gov with Cure HHT as lead sponsor.

NCT NCT06259292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06259292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHORUS: Comprehensive HHT (Hereditary Hemorrhagic Telangiectasia) Outcomes Registry of the United States
Lead sponsor
Cure HHT
Phase
Observational
Overall status
Recruiting
Start date
November 13, 2023
Completion date
November 30, 2033
Enrollment
10,000 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

arteriovenous malformations, cerebral arteriovenous malformations, epistaxis, gastrointestinal bleeding, hereditary hemorrhagic telangiectasia, telangiectasia, vascular malformation